121361. |
- Lindgren, Stefan, et al.
(författare)
-
Därför ändras läkarutbildningen
- 2005
-
Ingår i: Sydsvenska dagbladet. - 1104-0068.
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
121362. |
|
|
121363. |
|
|
121364. |
- Lindgren, Stefan, et al.
(författare)
-
Immunsvar och inflammation vid Crohns sjukdom. Snart mojligt driva diagnostiken langre och utveckla mer specifika lakemedel
- 1999
-
Ingår i: Läkartidningen. - 1652-7518. ; 96:1-2, s. 52-55
-
Tidskriftsartikel (refereegranskat)abstract
- The chronic inflammation in Crohn's disease may be caused by aggressive response to bacterial antigens normal to the gut. Genetic and environmental factors modify the inflammatory response evoked by damage to the mucosal gut barrier. Genetic factors may also determine the subsequent course of chronic inflammation. Further elucidation of the pathogenesis might improve our understanding of the heterogenous nature of Crohn's disease, thus enabling the disease to be subtyped and individualised therapy directed primarily at down-regulation of helper T-cell-1 response to be developed.
|
|
121365. |
|
|
121366. |
|
|
121367. |
- Lindgren, Stefan, et al.
(författare)
-
Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients : A randomized, controlled, evaluator-blind, multicentre study
- 2009
-
Ingår i: Scandinavian Journal of Gastroenterology. - : Informa UK Limited. - 0036-5521 .- 1502-7708. ; 44:7, s. 838-845
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. Patients with inflammatory bowel disease (IBD) often have low iron stores or anaemia. There is controversy about whether iron should be supplemented orally or intravenously (i.v.). The purpose of this study was to investigate whether treatment with intravenous iron is superior to treatment with oral iron. The primary end-points were response and remaining anaemia at the end of treatment (EOT).Material and methods. Ninety-one patients with IBD and anaemia (B-Hb <115 g/L) were randomized to oral iron sulphate (n=46) or intravenous iron sucrose (n=45) treatment for 20 weeks.Results. Forty-three patients in the intravenous iron group completed the study compared to 35 patients in the oral iron group (p=0.0009). Only 22 patients (48%) tolerated the prescribed oral dose, and 52% reduced the dose or withdrew from treatment because of poor tolerance. At EOT, 47% patients in the oral iron group increased their B-Hb by ≥20 g/L, compared with 66% in the intravenous iron group (p=0.07). In the oral iron group, 41% still had anaemia versus 16% of the patients in the intravenous iron group (p=0.007), and 22% versus 42% reached their reference B-Hb level (p=0.04). Treatment with intravenous iron sucrose improved iron stores faster and more effectively than oral iron (p=0.002). Under treatment with intravenous iron, 74% of the patients had no anaemia and normal S-ferritin levels (>25 µg/L) at EOT compared with 48% of patients receiving oral iron (p=0.013).Conclusions. Treatment with intravenous iron sucrose is effective, safe, well tolerated and superior to oral iron in correcting haemoglobin and iron stores in patients with IBD.
|
|
121368. |
- Lindgren, Stefan, et al.
(författare)
-
Järnbrist och järnbristanemi är globala hälsoproblem
- 2015
-
Ingår i: Läkartidningen. - 0023-7205. ; 112, s. 1-3
-
Tidskriftsartikel (refereegranskat)abstract
- Iron deficiency and iron deficiency anemia are global health problems leading to deterioration in patients' quality of life and more serious prognosis in patients with chronic diseases. The cause of iron deficiency and anemia is ususally a combination of increased loss and decreased intestinal absorption and delivery from iron stores due to inflammation. Oral iron is first line treatment, but often hampered by intolerance. Intravenous iron is safe, and the preferred treatment in patients with chronic inflammation and bowel diseases. The goal of treatment is normalisation of hemoglobin concentration and recovery of iron stores. It is important to follow up treatment to ensure that these objectives are met and also long-term in patients with chronic iron loss and/or inflammation to avoid recurrence of anemia.
|
|
121369. |
- Lindgren, Stefan
(författare)
-
Letter from the president.
- 2007
-
Ingår i: European Journal of Internal Medicine. - : Elsevier BV. - 1879-0828 .- 0953-6205. ; 18:2, s. 85-86
-
Tidskriftsartikel (refereegranskat)
|
|
121370. |
- Lindgren, Stefan, et al.
(författare)
-
Leversjukdomar i fokus för svensk forskning.
- 2010
-
Ingår i: Läkartidningen. - : Swedish Medical Association. - 0023-7205 .- 1652-7518. ; 107:21, s. 1378-1378
-
Tidskriftsartikel (refereegranskat)
|
|